| Epilepsy is a common chronic neurological disease. About30%of epilepsypatients suffer cognitive impairment with the cause of primary disease, seizures,antiepileptic drugs, surgery and so on. The treatments of epilepsy includingantiepileptic drugs, surgery, ketogenic diet and vagus nerve stimulation aresymptomatic treatment, without considering the treatment of cognitiveimpairment. Children and the elderly have the higher incidence of epilepsy, andthe cognitive function of them needs more attention. Nowadays, the drug whichimproves cognitive function is donepezil. However, donepezil may have the sideeffect that aggravates epilepsy. Therefore, our goal is to find a new drug whichimproves cognitive impairment which induced by epilepsy. Polyenephosphatidyl choline (PPC), an almost non-toxic compound, has a variety ofbiological functions with the active ingredient contains polyunsaturated fat bases.Numbers of studies have confirmed that the polyene phosphatidylcholine cancontrol seizure attacks, improve cognitive function, and protect the function of liver. The aim of this study is to discuss the protective effects of polyenephosphatidyl choline on brain and liver of lithium chloride-pilocarpine inducedepilepsy model, which will provide a theoretical basis for clinical application.ObjectiveTo confirmed that the polyene phosphatidylcholine protect the cognitivefunction function on lithium chloride-pilocarpine induced epilepsy in rats andreduce the liver damage from sodium valproate.MethodsMale SD rats were randomly divided into four groups: normal controlgroup (Normal), epilepsy model group (EP), sodium valproate treatment group(VPA) and sodium valproate add polyene phosphatidyl choline treatment group(VPA+PPC). Every group were given medication two weeks after epilepsymodels were made successfully, Normal and EP group was treated withintragastric gavage of normal saline (10ml/kg); VPA group were treated withintragastric gavage of sodium valproate (300mg/kg) while VPA+PPC groupwas treated with intragastric gavage of sodium valproate (300mg/kg) andpolyene phosphatidylcholine (400mg/kg), all groups were treated for continuous4weeks or6weeks, once a day. Then seizure frequency monitoring, Morriswater maze tests, Nissl staining of hippocampal tissue, serum biochemicaltesting and HE staining of liver tissue were taken.ResultsCompared with the EP group, there was a decline seizure frequency inVPA+PPC group and VPA group (P<0.05). The results of Morris water mazeshowed that EP group had a much longer escape latency than Normal group (P<0.05); while escape latency of VPA+PPC group was significantly shorterthan VPA group (P<0.05); Swimming distance and time of VPA+PPC groupwere longer than VPA group and EP group in the target quadrant (P<0.05);VPA+PPC group owned lower ALT and AST level than VPA group (P<0.05).ConclusionPolyene phosphatidyl choline can improve epilepsy induced cognitiveimpairment and valproate induced liver toxicity. |
PDF Full Text Request